Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori. Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden.
Frequently asked questions
What sector does Cinclus Pharma (CINPHA) operate in?
Cinclus Pharma belongs to the Other sector and operates in the Drug Manufacturers - Specialty & Generic industry.
What is Cinclus Pharma (CINPHA) current stock price?
As of the latest data, Cinclus Pharma stock price is SEK 11.98, with a previous close of SEK 11.82. Cinclus Pharma gained SEK 0.16 in the last trading session, representing a 1.35% increase.
What is Cinclus Pharma (CINPHA) current market capitalization?
Cinclus Pharma market cap is approximately 557.52 million.
What is Cinclus Pharma (CINPHA) Earnings Per Share (EPS)?
The trailing EPS is -SEK 5.14, and the forward EPS is -SEK 5.65.
Does Cinclus Pharma (CINPHA) pay dividends?
No. Cinclus Pharma does not pay a dividend.
What is Cinclus Pharma (CINPHA) beta (volatility) score?
Cinclus Pharma has a beta of -0.054, indicating lower volatility than the overall market.
